Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 969

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 969
---
.S.C. § 18001 et seq.); each
to the extent applicable to the Company or any of its Subsidiaries or their businesses or activities or Company Products;

(z)
“” means the sum of (A) any and all losses incurred or accrued from the Closing Date through the six (6) month anniversary of the Closing Date resulting from a breach of the representations and
warranties set forth in ; , , that in determining whether any breach of has occurred and in determining the amount of losses arising from any
breach of , the terms “material,” “Material Adverse Effect” and words of similar import shall be disregarded and given no effect (B) any and all losses incurred or accrued
from the Closing Date through the six (6) month anniversary of the Closing and any estimated losses to be incurred in connection with any of the matters discussed in as reasonably determined or
estimated by Parent, including any reasonable attorneys’ fees and disbursements.

A-56

(aa) “” means, with respect to any Person, (i) all
obligations of such Person for borrowed money, or with respect to unearned advances of any kind to such Person, (ii) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (iii) all capitalized lease
obligations of such Person, (iv) all obligations of such Person under installment sale contracts, (v) all guarantees and arrangements having the economic effect of a guarantee of such Person of any Indebtedness of any other Person, and
(vi) all obligations or undertakings of such Person to maintain or cause to be maintained the financial position of others or to purchase the obligations of others;

(bb) “” means the quotient of (i) the Company Initial Share Consideration
(ii) the Company Fully Diluted Common Stock, rounded down to six (6) decimal places;

(cc) “” means a Company Stock Option that is unexpired, unexercised and outstanding immediately prior to the Effective Time and has a per
share exercise price that is $0.64 or less.

(dd) “”means the actual knowledge, of the individuals listed on of the Company Disclosure Letter, after reasonable inquiry of the persons that
would reasonably be expected to have actual knowledge of the applicable matter;

(ee) “” means the Company’s
product candidate that is referred to as KVA12123 and that is an anti-VISTA antagonist mAb immunotherapy to address tumor